July 24 (Reuters) - Britain's health regulator said on

Wednesday it has authorised Pfizer ( PFE ) and BioNTech's

updated COVID-19 vaccine that targets the JN.1

subvariant for use in infants, children and adults.

The Medicines and Healthcare products Regulatory Agency

(MHRA) said it has approved four forms of the adapted Comirnaty

JN.1 vaccine after reviewing its safety, quality and

effectiveness.

The regulator also said it would keep the safety of the

vaccine under close review.

Globally, regulators like the European Medicines Agency and

the World Health Organisation are recommending that COVID

vaccine manufacturers update their vaccines to target the JN.1

variant, although the U.S. Food and Drug Administration

suggested the targeting of the newer KP.2 variant, if feasible.